Quanterix CORP

Quanterix Corporation shareholders elected directors and ratified auditors but rejected the proposed amendment to the 2017 Equity Incentive Plan.

Quanterix Corporation announced the appointment of Jason Faessler as its new Chief Financial Officer and Treasurer, effective June 22, 2026, bringing extensive finance leadership experience from the life science tools industry.

Quanterix Corporation announced the appointment of Anthony Catalano as Chief Operating Officer and a leadership transition for Michael Miller.

Quanterix Corporation announced the planned departure of its Chief Financial Officer, Vandana Sriram, effective June 15, 2026, with a search for her successor underway.

Quanterix reported a 20% year-over-year revenue increase to $36.4 million for Q1 2026, driven by growth in its Alzheimer's diagnostics business and reaffirming its full-year guidance.

Quanterix announced its fourth quarter and full year 2025 financial results, reporting revenue stabilization and significant progress towards achieving cash flow breakeven in the second half of 2026.

Quanterix Corporation reported a 20% increase in total revenues for the first quarter of 2026, driven by the Akoya Biosciences acquisition, while also detailing strategic adjustments and a significant impairment charge.

Quanterix reported a significantly wider net loss in Q3 2025, driven by acquisition costs, restructuring, and macroeconomic pressures, despite revenue growth from the Akoya Biosciences acquisition.

Quanterix Corporation reported a significant increase in net loss for Q2 2025, driven by declining revenues and a $6.4 million goodwill impairment charge, while strategically acquiring Akoya Biosciences and implementing cost reductions.

Quanterix Corporation announces its Q1 2025 financial results, a restructuring plan to reduce operating costs, and an update on its agreement to acquire Akoya Biosciences.

Quanterix Corporation released its third quarter 2024 financial results, which included a restatement of prior period financials and updates on strategic initiatives.

Quanterix Corporation has filed an amended quarterly report to restate its financials due to an error in inventory valuation and other unrelated adjustments.

Quanterix reports increased revenue driven by strategic acquisitions and progress in Alzheimer's diagnostics, despite a significant rise in net loss and macroeconomic headwinds.

Quanterix Corporation files an amendment to its annual report to include information required by Part III of Form 10-K, which was initially omitted.

Quanterix's FY2024 results show revenue growth and strategic acquisitions aimed at expanding its presence in diagnostics and biomarker analysis.

Quanterix Corporation has filed an amended annual report to restate its financial statements for the past three years due to an error in inventory valuation and other unrelated errors, revealing a material weakness in internal controls.

Quanterix Corporation has updated its Non-Employee Director Compensation Policy, outlining changes to cash retainers and equity awards for non-employee board members, effective January 1, 2024.

Michael Francis Miller, Chief Technology Officer of Quanterix Corp, reported multiple transactions in common stock on July 15, 2026.

Jason F. Faessler, Chief Financial Officer of Quanterix Corp, received 141,820 shares of common stock on July 15, 2026.

Scott Mendel, a Director at Quanterix Corp, reported transactions involving restricted stock units and common stock on July 8, 2026.

Myla Lai-Goldman, a Director at Quanterix Corp, has reported transactions involving restricted stock units and common stock.

Director Scott Mendel of Quanterix Corp. has reported the acquisition of 3,456 shares of common stock, valued at $4.34 per share, as compensation for board services.

William P. Donnelly, a Director at Quanterix Corp, reported the acquisition of 5,472 shares of common stock on July 1, 2026, valued at $4.34 per share, as compensation for board services.

Quanterix Corporation has announced its 2026 Annual Meeting of Stockholders will be held virtually on June 9, 2026, with key proposals including director elections and equity plan amendments.

Quanterix Corporation adjourned its 2025 Annual Meeting of Stockholders to allow more time for voting on proposals to eliminate supermajority voting requirements.

Quanterix Corporation will hold its 2025 annual meeting to vote on board declassification, executive compensation, and auditor ratification, following recent board changes and financial restatements.

Kent Lake Partners, owning 7.7% of Quanterix, is soliciting proxies to vote against the proposed merger with Akoya Biosciences, believing it is not in the best interests of Quanterix stockholders.

Quanterix Corporation will hold its annual stockholder meeting on June 3, 2024, to vote on the election of directors, executive compensation, and the ratification of Ernst & Young LLP as the independent accounting firm.

Quanterix Corporation has scheduled its 2024 annual meeting of stockholders for June 3, 2024, to elect directors, approve executive compensation, and ratify the appointment of its independent accounting firm.

Activist investor Kent Lake Partners LP has reduced its beneficial ownership in Quanterix Corp to 4.5% through recent share sales, while simultaneously re-nominating three individuals for election to the Board of Directors at the rescheduled 2025 annual meeting.

Akoya Biosciences, Inc. has terminated its Voting and Support Agreement with certain Quanterix Corp. stockholders, a procedural step following the execution of an Amended and Restated Agreement and Plan of Merger.

Quanterix Corporation has amended its merger agreement with Akoya Biosciences, Inc., outlining revised acquisition terms and securing voting support from key Akoya shareholders representing 55.6% of outstanding common stock.

Activist investor Kent Lake Partners LP, along with its affiliates and Benjamin Natter, has formally nominated three director candidates for election to Quanterix Corporation's Board of Directors at the 2025 annual meeting, holding a 6.9% beneficial ownership stake.

Activist investor Kent Lake Partners, holding a 5.91% stake in Quanterix Corp, has publicly opposed the company's proposed stock merger with Akoya Biosciences, calling it a 'bailout' that significantly undervalues Quanterix and risks its financial stability.

Quanterix Corporation has entered into a definitive agreement to acquire Akoya Biosciences, Inc. through a merger, with Akoya becoming a wholly-owned subsidiary of Quanterix, significantly altering the combined entity's ownership structure and board composition.

Portolan Capital Management, LLC and George McCabe have filed a Schedule 13G reporting a 6.25% beneficial ownership stake in Quanterix Corp.

Ameriprise Financial, Inc. has filed a Schedule 13G, reporting beneficial ownership of 7.5% of Quanterix Corp. common stock as of March 31, 2026.

Ameriprise Financial, Inc. has filed a Schedule 13G, reporting beneficial ownership of 990,224 shares of Quanterix Corp. common stock, representing 2.1% of the class.

The Vanguard Group has reported zero beneficial ownership in Quanterix Corp common stock following an internal realignment.

Ameriprise Financial, Inc. and its subsidiaries have reported a beneficial ownership of 10.7% in Quanterix Corp. common stock as of December 31, 2025.

Telegraph Hill Partners and its affiliates have reported a 5.4% beneficial ownership stake in Quanterix Corp, totaling 2,504,648 shares of common stock.